Robust Growth Visible for Doxazosin Mesylate Market 2020-2025 | Global Key Vendors - Pfizer, Hefei Lifeon Pharma, Kangmei Pharma, Zhejiang CONBA Pharma

Global Doxazosin Mesylate Market Synopsis:

The report covers a forecast and an analysis of the Doxazosin Mesylate Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Doxazosin Mesylate Market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Doxazosin Mesylate Market on a global level.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/275414 .

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Doxazosin Mesylate Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

On the basis of Regional analysis, North America and Europe holds major share in global Doxazosin Mesylate market. Moreover, Asia-Pacific is expected to record higher growth rate in Doxazosin Mesylate Market during the forecast year.

Global Key Players:

1 Pfizer

2 Hefei Lifeon Pharmaceutical

3 Shandong ShanChuan Pharmaceutical

4 Kangmei Pharmaceutical

5 Zhejiang CONBA Pharmaceutical and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Doxazosin Mesylate Market Report 2020” @ https://www.businessindustryreports.com/buy-now/275414/single .

Product Type Segmentation

1 Oral Immediate-release Tablet (1 mg, 2 mg, 4 mg, and 8 mg)

2 Oral Extended-release Tablet (4 mg and 8 mg)

Industry Segmentation

1 Hospital

2 Retail Pharmacy

Global Medical Industry News:

Pfizer (October 07, 2020) - Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment - Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.

AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe hemophilia A. The primary endpoint is impact on annual bleed rate (ABR) through 12 months following treatment with giroctocogene fitelparvovec, compared to ABR on Factor VIII (FVIII) replacement therapy collected in the Phase 3 lead-in study period. Participants will be analyzed throughout the 5-year study period following the single infusion to further assess the durability and efficacy.

“The initiation of the pivotal Phase 3 dosing study of giroctocogene fitelparvovec is a significant achievement for Pfizer as we continue our longstanding commitment to improving care for the hemophilia community,” said Brenda Cooperstone, Chief Development Officer, Rare Disease, Pfizer Global Product Development. “Enrollment in the lead-in study is progressing well and recruitment is on track for Phase 3. Given the Phase 1/2 study findings to date, we believe that giroctocogene fitelparvovec has the potential to sustain factor levels and reduce annual bleed rates, suggesting this one-time gene therapy could potentially transform the standard of care for eligible patients worldwide.”

Data from the Phase 3 lead-in study will provide a baseline for patients evaluated in the Phase 3 study. Updated Phase 1/2 data announced at a Pfizer investor event on September 15, 2020 demonstrated that giroctocogene fitelparvovec was generally well tolerated. Each of the five patients in the high dose cohort sustained FVIII activity levels without bleeds or the need for prophylactic factor through up to 85 weeks. Factor VIII activity levels were sustained at a clinically meaningful level, with a geometric mean of ~71% when measured between the weeks of 9 and 52.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/275414 .

Major Points in Table of Contents:

Global Doxazosin Mesylate Market Report 2020

1 Doxazosin Mesylate Product Definition

2 Global Doxazosin Mesylate Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Doxazosin Mesylate Shipments

2.2 Global Manufacturer Doxazosin Mesylate Business Revenue

2.3 Global Doxazosin Mesylate Market Overview

2.4 COVID-19 Impact on Doxazosin Mesylate Industry

3 Manufacturer Doxazosin Mesylate Business Introduction

3.1 Pfizer Doxazosin Mesylate Business Introduction

3.2 Hefei Lifeon Pharmaceutical Doxazosin Mesylate Business Introduction

3.3 Shandong ShanChuan Pharmaceutical Doxazosin Mesylate Business Introduction

3.4 Kangmei Pharmaceutical Doxazosin Mesylate Business Introduction

3.5 Zhejiang CONBA Pharmaceutica Doxazosin Mesylate Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.